ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Study Protocol

Comparison between Tazarotene 0.05% gel and Adapelene 0.1% gel in acne patients

[version 1; peer review: 1 approved, 1 approved with reservations]
PUBLISHED 15 Nov 2023
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Datta Meghe Institute of Higher Education and Research collection.

Abstract

Background: Acne is an extremely common skin condition, which has a major social and psychological impact on young patients. Retinoids have been a mainstay of anti-acne therapy. Older generation agents are slowly replaced by newer generation ones like tazarotene and adapalene as they exhibit lower toxicologic risk and less side effects and they effectively reduce the comedones and inflammatory lesions. This study throws light on effectiveness of topical Adapalene gel- 0.1% and Tazarotene gel-0.05% in order to find out a suitable option with lesser side effects for acne patients.

Methods: After clearance from the institutional ethics committee, acne patients aged >12-35 years at the outpatient area of the Dermatology department, AVBRH, Jawaharlal Nehru Medical College, Sawangi, Wardha, were enrolled in the study. Patients will be randomly assigned in two groups wherein group A will be prescribed Tazarotene-0.05% gel and group B prescribed Adapalene-0.1% gel along with Tab Azithromycin-500mg thrice weekly for 12 weeks for both groups. Patients will be clinically assessed on every 4th, 8th and 12th week. Global acne score system will be applied at enrolment and at each subsequent follow-up for evaluation.

Keywords

Acne vulgaris tazarotene , adapelene

Introduction

The development of papules which are erythematous pustules and sometimes nodules and pseudocysts all often occur in acne patients.1 More than 85% of teenagers are affected, making it a very common skin disorder in younger population.2 The main pathogenic mechanisms include propionibacterium acnes microbiological colonisation of pilosebaceous units, which promotes perifollicular inflammation, oil gland secretion stimulation by androgens, abnormal infundibular epithelial keratinization, and hyperkeratinization.3 When it comes to ultrastructure, it can be shown that follicular keratinocytes in comedones contain more desmosomes and tonofilaments. A pilo-sebaceous follicular disorder with persistent inflammation that can affect young adults and has negative social and psychological outcomes. Regardless of colour or ethnicity, everyone between the ages of 12 and 17 must have occasionally come into contact with a white head or a black head. Therefore, it is therefore crucial to manage acne at the earliest possible stage.4

Since they have so many different mechanisms of action, retinoids have been a crucial part of anti-acne therapy. They successfully lessen the inflammatory lesions and comedones. Newer generation medications like Tazarotene and Adapalene are gradually replacing the long-established Tretinoin and Isotretinoin. These are selective for a subset of retinoic acid receptors, also unlike Tretinoin, that exhibits lower toxicologic risk and results in less side effects.5 This study focuses primarily on the effectiveness of Adapalene gel of 0.1% applied topically and Tazarotene gel of 0.05% applied topically in order to find a modality of treatment for facial acne vulgaris that is more effective because very few clinical trials based on the basis of effectivity and toleranace of tazarotene gel of 0.05% to that of adapelene gel of 0.1% have been performed.

Rationale

One of the skin conditions that causes emotional trauma, feelings of inferiority, and insecurity, acne is one of the skin conditions that today’s teenagers worry about the most. Consequently, it is now important to manage acne at an early stage.3

A retinoic acid receptor-specific drug is tazarotene. It inhibits keratinocyte growth, differentiation, and markers of inflammation. The drug also increases the expression of three distinct genes called TIG-1, TIG-2, and TIG-3 are the three genes that may have an antiproliferative effect. Instead of an indirect effect linked to the improvement of disease, the result of tazarotene on these indicators is likely an influence on expression of genes.6 Retinoids are frequently used as a last resort to cure acne, but they also have a few negative effects. Finding a retinoid with fewer side effects is therefore necessary and preferred. Additionally, relatively few research has been done in India regarding the effectiveness of 0.05% tazarotene. Therefore, it is crucial to create a study that focuses on comapritive study between these two. Also this study will help us infer to which topical formulations are effective for acne treatment wherein oral medication need not be given or are contraindicated.

Aims and objectives

The aim of this study is the comparison of the effectivity of tazarotene gel of 0.05% to that of adapelene gel of 0.1% in treating acne vulgaris on the face.

The objectives are as follows:

  • 1) To research how well topical Tazarotene 0.05% gel works to treat acne vulgaris on the face.

  • 2) To research the effectiveness tazarotene gel of 0.05% to that of adapelene gel of 0.1%.

  • 3) To evaluate how well Adapalene gel of 0.1% and topical Tazarotene gel of 0.05% treat acne on the face.

  • 4) To investigate the multiple adverse effects of tazarotene gel of 0.05% and adapalene gel of 0.1%.

Methods

Study design

The study will be a randomized, single blinded, parallel group, case controlled trial. Patients suffering from acne vulgaris patients with age >12-35 years attending the the outpatient unit of the Department of Dermatology, AVBRH Sawangi Meghe, Wardha. The study period is two years; from June 2022 to September 2024.

Sample size

Prevalance of acne in group of following age of 12-35 years is a range of 75-80%

Prevalance of acne vulgaris in an age group of 12-35 years is a range of 75-80%

With value of significance 0.05

A 80.27% reduction in acne vulgaris lesions was shown with the usage of 0.1% adapelene.

B 53.13% reduction in acne vulgaris lesions was shown with the usage of 0.1% tazorotene.7

nA=knBandnBpA1pA/k+pB1pBz1ɑ+z1β/2/pApB§2

pAAnticipated response rate with standard treatment0.8
PBAnticipated response rate with new treatment0.53
ΑSet level of Type-1 Error (Usual Value 0.05)0.05
ΒSet level of Type-2 Error (Usual value 0.2)0.2
DAbsolute difference in Ps and Pn0.27
ΔSet level of equivalence0.05
Z1-αZ associated with α1.644854
Z1-β/2Z associated with selected β1.281552
KSampling Ratio nA/nB (Usual values 1-3)1
NHere, K = 1, so nA = nB (By Method-1, Method-2)73

Sample size in each group: 73

Total sample size: 146

Inclusion criteria

  • 1) Patients irrespective of gender.

  • 2) Patients with age >12–35 years.

  • 3) Patients willing to participate.

  • 4) Patients with acne grade (based on Global Acne Scoring Criteria): I, II, III.

Exclusion criteria

  • 1. History of hypersensitivity or allergic reactions to retinoids.

  • 2. Patients with a history of photosensitivity.

  • 3. Females who are pregnant, lactating mothers and married women planning for pregnancy.

  • 4. Patient with photo aggravated disorders.

Methods

Patients who have been clinically diagnosed with acne vulgaris with age >12-35 years who would be registered from June 2022 to September 2024 at the OPD of department of Dermatology, JNMC Wardha, Sawangi Wardha with clearance from the institutional ethics committee (ECR/440/Inst/MH/2013/RR-2019). All patients who choose to participate voluntarily will be asked for written informed consent. a thorough background containing information on your age, gender, educational level, socioeconomic standing, employment, marital status, occupation, past drug use, and the length of the application will be taken.

Patients will be randomized into one of two groups (Group A and Group B) by straight forward randomization by computer-generated numbers. Group A will be prescribed Tazarotene 0.05% gel along with Tab Azee 500 mg thrice weekly for 12 weeks and Group B will be prescribed Adapalene 0.1% gel along with Tab Azee 500 mg thrice weekly.

For assessment of improvement a system of scoring will be called Global Acne Scoring (Table 1) be used when the patient is being enrolled and also with every consecutive follow-up.8

Table 1. Global acne scoring criteria.

LocationGrade
Forehead2
Right cheek2
Left cheek2
Nose1
Chin1
Chest & upper back3

Global acne scores:

0 = NONE

1-18 = MILD

19-30 = MODERATE

31-38 = SEVERE

>39 = VERY SEVERE

Total counts of papules, comedones, nodules, pustules, at the time of the first visit and then in every consecutive follow-up will be noted down. It will also be mentioned that retinoids have negative effects, including dryness, erythema, acne flare-ups, and itching. The method application that will be explained to the patient will include the application of tazarotene on the acne lesions overnight on a properly washed clean face. A routine moisturizer will be prescribed to a patient to combat the dryness that may be a side effect.

The study will have a total 12 weeks (3 months) follow-up duration. The patient will be called for follow-up every fortnight during this tenure.

Outcome measure

Total clearance of lesions, improvement in numbers of counts of comedones, papules, pustules, and nodules, improvement in global acne scoring, side effects i.e. dryness, erythema, itching, and flare-up of acne will be studied. To observe the improvement in the acne of patients based on Global Acne Scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, and the side effects that arise with the usage of 0.05% tazarotene and 0.1% adapalene.

Statistics

For our statistical analysis, we will apply the necessary parametric and non-parametric tests. The SPSS 16.0 version will be used to analyse the data collected. For the comparison of qualitative data between two variables, descriptive statistics like proportion, mean, and standard deviation will be employed, while the chi square test and other statistics that are inferential like chi square test will be employed. Using independent T tests (unpaired t tests) and paired t tests, quantitative data between two variables will be compared before and after. The 95% level will act as the fixed upper bound for significance if the p-value is less than 0.05.

Scope

  • 1. To add newer topical drugs for reating patients of facial acne.

  • 2. To study the effect of tazarotene with other systemic drugs in combinations.

  • 3. To study the effect of tazarotene with combinations with other topical agents.

Study status

The study is ongoing.

Discussion

A study determined that tazarotene 0.1% cream and tretinoin 0.05% cream are individually effective and tolerable in the treatment of mild to moderate acne vulgaris. Patients were alloted in a group of two, Group A and Group B, based on the number of comedones.9

Bershad et al. determined that Tazarotene shows improvement patients of acne vulgaris when used topically. A safe and efficient topical treatment for acne appears to be topical tazarotene with the exception of ovulating females, in whom proper safety precautions should be taken.10

Acne on face was treated with tazarotene gel of 01% and adapelene gel of 0.1%. in a study in 106 acne patients. Every patient had a thorough clinical examination. The efficiency of daily use of tazarotene gel of 0.05% and adapalene gel of 0.1% for the treatment of facial acne vulgaris were evaluated in a multicenter, double-blind, randomised comparison research.11

GF Webster and colleagues found that the treatment with tazarotene gel has been associated with considerably higher rates of success when compared to adapalene as well as significantly lower levels of total disease severity, lesion count of non inflammatory type and inflammatory type. In conclusion, tazarotene gel of 0.1% was more effective than adapalene gel of 0.1% and was also a more cost-effective treatment.12 Our findings will be in line with the said research.

Conclusion

This is a randomised controlled study wherein we compare the efficacy of 0.05% tazarotene gel to 0.1% adapelene gel in grade I to III patients with acne vulgaris. This study’s significance lies in the addition of newer topical medications and the examination of the interaction between tazarotene and other systemic medications. Also to study the effect of tazarotene with combinations with other topical agents that will help us find better effective modality for patient of acne on the face.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 15 Nov 2023
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Jaiswal S and Jawade S. Comparison between Tazarotene 0.05% gel and Adapelene 0.1% gel in acne patients [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2023, 12:1472 (https://doi.org/10.12688/f1000research.139034.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 15 Nov 2023
Views
1
Cite
Reviewer Report 25 May 2024
PRASETYADI MAWARDI, Sebelas Maret University, Surakarta, Indonesia 
Approved
VIEWS 1
This study opens new horizons in the use of vitamin A acid derivatives, Tazarotene and adapalene in the management of Acne Vulgaris (AV). In various references, these two topical drugs are said to have fewer side effects than tretinoin. However, ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
MAWARDI P. Reviewer Report For: Comparison between Tazarotene 0.05% gel and Adapelene 0.1% gel in acne patients [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2023, 12:1472 (https://doi.org/10.5256/f1000research.152274.r240342)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
1
Cite
Reviewer Report 06 Mar 2024
Isabel Cristina Valente Duarte de Sousa, Hospital ABC Campus Santa Fe, Mexico City, Mexico 
Approved with Reservations
VIEWS 1
"General comments
Please revise the text for proper English grammar, since there are many mistakes throughout the text
The study design is not clear. Were the retinoids applied all over the face or just over active acne lesions?
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Duarte de Sousa ICV. Reviewer Report For: Comparison between Tazarotene 0.05% gel and Adapelene 0.1% gel in acne patients [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2023, 12:1472 (https://doi.org/10.5256/f1000research.152274.r250095)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 15 Nov 2023
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.